Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Nadine Vollack-Hesse, Olga Oleshko, Sonja Werwitzke, Barbara Solecka-Witulska, Christoph Kannicht, Andreas Tiede

Blood (2021) 137 (8): 1072–1081.

https://doi.org/10.1182/blood.2020006468

Published: 2021

Includes: Supplemental data

Journal Articles

Vasomotor hyperresponsiveness in SCD

Valentine Brousse, Philippe Connes

Blood (2020) 136 (10): 1120–1121.

https://doi.org/10.1182/blood.2020007070

Published: 2020

Journal Articles

The Novel Role That Nrf2 Plays in Erythropoiesis during Aging

Serge Cedrick Toya Mbiandjeu, Alessandro Mattè, BSc,PhD, Enrica Federti, PhD, Massimiliano Perduca, Immacolata Andolfo, Achille Iolascon, MD PhD, Maria Teresa Valenti, PhD, Arianna Pisani, Luca Dalle Carbonare, MD, Pietro Pucci, Angela Amoresano, Mohandas Narla, DSc, Lucia De Franceschi, MD

Blood (2019) 134 (Supplement_1): 3502.

https://doi.org/10.1182/blood-2019-125920

Published: 2019

Journal Articles

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Blood (2019) 134 (Supplement_1): 4319.

https://doi.org/10.1182/blood-2019-123331

Published: 2019

Journal Articles

Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators

Aparajita Hoskote Chourasia, PhD, Leah Fung, PhD, Brooke McElwee, BSc, Normand Richard, MSc, Imelda Lam, BSc, Eduardo Torres, MSc, Paul Erdman, MSc, Robert Sullivan, PhD, David Hecht, PhD, Kyle WH Chan, PhD, Frank Mercurio, PhD, David I Stirling, PhD

Blood (2019) 134 (Supplement_1): 3361.

https://doi.org/10.1182/blood-2019-131872

Published: 2019

Journal Articles

Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

Frank V. McL. Booth, MA MSc BM BCh, Johnny Mahlangu, Howard Levy, PhD MBBChir

Blood (2018) 132 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2018-99-111720

Published: 2018

Journal Articles

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Robert N Booher, PhD, Grzegorz S. Nowakowski, MD, Krish Patel, MD, Matthew A. Lunning, DO, Maria Elena S. Samson, B.S., Ruzanna Atoyan, MD, Anna W Ma, MS, Guang-Xin Xu, BS, Steven Dellarocca, B.S., Holly Modafferi, BS, Mylissa Borek, B.S., Zhidong Zhang, PhD, Jefferson Parker, PhD, Duncan Whitney, PhD, Hongwei Wang, MD, David P Tuck, MD, Anas Younes, MD

Blood (2018) 132 (Supplement 1): 4168.

https://doi.org/10.1182/blood-2018-99-117383

Published: 2018

Journal Articles

Minit-Livin Conjugated to Targeted Nanoparticles Inhibits Tumorigenicity

Ihab Abd Elrahman, BSc, MSc, Taher Nassar, PhD, Noha Khairi, MSc, Riki Perlman, PhD, Simon Benita, PhD, Dina Ben-Yehuda, MD

Blood (2018) 132 (Supplement 1): 4171.

https://doi.org/10.1182/blood-2018-99-118045

Published: 2018

Journal Articles

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Syed J. Mehdi, PhD, Sarah K Johnson, PhD, Sharmin Khan, Wen Ling, PhD, Randal Shelton, Joshua Epstein, DSc, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Carolina D. Schinke, MD, Sharmilan Thanendrarajan, MD, Brian A Walker, PhD, Cody Ashby, PhD, Faith E. Davies, MD, Gareth Morgan, MD, Shmuel Yaccoby, PhD

Blood (2018) 132 (Supplement 1): 1929.

https://doi.org/10.1182/blood-2018-99-116455

Published: 2018

Journal Articles

Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade ® and Jadenu TM

Justin Keen, PhD, Dave Miller, PhD, Simon Tulloch, BA MA BM BCh

Blood (2017) 130 (Supplement 1): 2215.

https://doi.org/10.1182/blood.V130.Suppl_1.2215.2215

Published: 2017

Journal Articles

NCOA4 Links Iron Bioavailability to DNA Metabolism

Giorgia Federico, PhD, Roberto Bellelli, PhD, Antonella Nai, PhD, Laura Silvestri, PhD, Clara Camaschella, MD, Achille Iolascon, MD PhD, Massimo Santoro, MD, Francesca Carlomagno, MD

Blood (2017) 130 (Supplement 1): 223.

https://doi.org/10.1182/blood.V130.Suppl_1.223.223

Published: 2017

Journal Articles

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Alexander Roeth, MD, Nagy Zsolt, MD PhD, Miklos Egyed, MD, Erica Winter, Joy Hsu, Andreas Dieckmann, Judith Anzures-Cabrera, Marie Mannino, Elana Fernandez, PhD, Gregor Jordan, Barbara Klughammer, PhD, Kenji Shinomiya, Naoki Kotani, Ido Paz-Priel, MD, Angelika Jahreis., MD, PhD

Blood (2017) 130 (Supplement 1): 4750.

https://doi.org/10.1182/blood.V130.Suppl_1.4750.4750

Published: 2017

Journal Articles

Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients

Syed Mehdi, Sharmin Khan, Wen Ling, Randal S Shelton, Joshua Epstein, DSc, Ricky D Edmondson, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E Davies, MD, Bart Barlogie, MD PhD, Gareth J Morgan, MD PhD, Shmuel Yaccoby, PhD

Blood (2016) 128 (22): 3304.

https://doi.org/10.1182/blood.V128.22.3304.3304

Published: 2016

Journal Articles

Sucrosomial Technology Is Able to Promote Ferric Iron Absorption: Pre-Clinical and Clinical Evidences

Elisa Brilli, PhD, Alessandra Romano, MD PhD, Angela Fabiano, PhD, Ylenia Zambito, PhD, Francesco Di Raimondo, MD, Germano Tarantino, MD

Blood (2016) 128 (22): 3618.

https://doi.org/10.1182/blood.V128.22.3618.3618

Published: 2016

Journal Articles

Ferritinophagy and Cell Cycle Control

Francesca Carlomagno, MD PhD

Blood (2016) 128 (22): SCI-20.

https://doi.org/10.1182/blood.V128.22.SCI-20.SCI-20

Published: 2016

Journal Articles

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Darja Karpova, PhD, Michael P. Rettig, PhD, Linda Eissenberg, PhD, Julie Ritchey, Matthew Holt, Richard Heier, Stacy Arnett, PhD, Marvin Meyers, PhD, David W. Griggs, PhD, Peter Ruminski, PhD, Dwight Morrow, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 659.

https://doi.org/10.1182/blood.V128.22.659.659

Published: 2016

Journal Articles

SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3

Shirong Li, PhD, Jing Fu, PhD, Jing Wu, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2016) 128 (22): 4477.

https://doi.org/10.1182/blood.V128.22.4477.4477

Published: 2016

Journal Articles

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Alonso Ricardo, PhD, Michelle Arata, MS, Steven DeMarco, PhD, Ketki Dhamnaskar, MS, Robert Hammer, PhD, Masha Fridkis-Hareli, PhD, Vaishnavi Rajagopal, PhD, Kathleen Seyb, PhD, Guo-Qing Tang, PhD, Sylvia Tobe, PhD, Douglas Treco, PhD

Blood (2015) 126 (23): 939.

https://doi.org/10.1182/blood.V126.23.939.939

Published: 2015

Journal Articles

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Niranjan S. Rao, PhD, Sanjeeva Reddy, PhD, Gupta Sandeep, PhD, Nitin K Damle, PhD, Venkatesan M Aranapakam, PhD, Scott Thompson, PhD, Roger Smith, PhD, Terry Plasse, MD, Penelope Bristow, MS, Anthony Tolcher, MD, Kyriakos P Papadopoulos, MD, Amita Patnaik, MD, Drew W Rasco, MD

Blood (2015) 126 (23): 4009.

https://doi.org/10.1182/blood.V126.23.4009.4009

Published: 2015

Journal Articles

Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice

Douglas Drager, Sue Patarroyo-White, Hoson Chao, Ayman Ismail, PhD, Jiayun Liu, Amy M Holthaus, BS, MS, Ekta Chhabra, John Kulman, PhD, Volker Schellenberger, PhD, Tongyao Liu, Robert Peters, PhD

Blood (2015) 126 (23): 3492.

https://doi.org/10.1182/blood.V126.23.3492.3492

Published: 2015

NARROW

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Vasomotor hyperresponsiveness in SCD

The Novel Role That Nrf2 Plays in Erythropoiesis during Aging

Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia

Targeting AML: The Development of Two Functionally and Mechanistically Distinct Classes of Cereblon-Mediated Protein Homeostatic Modulators

Opportunities for Improvement: The Lot of the Inhibitor Patient Is Not a Happy One

Preclinical Activity of IRAK4 Kinase Inhibitor CA-4948 Alone or in Combination with Targeted Therapies and Preliminary Phase 1 Clinical Results in Non-Hodgkin Lymphoma

Minit-Livin Conjugated to Targeted Nanoparticles Inhibits Tumorigenicity

Proliferation and Molecular Risk Score of Low Risk Myeloma Cells Are Increased in High Risk Microenvironment Via Augmented Bioavailability of Growth Factors

Phase I Trial Results of a Solid Dispersion Formulation of Deferasirox with Enhanced Bioavailability Relative to Exjade ® and Jadenu TM

NCOA4 Links Iron Bioavailability to DNA Metabolism

The SMART-IgG Anti-hC5 Antibody (SKY59/RO7112689) Has Favorable PK, PD, Subcutaneous Bioavailability, and Safety Profile in Phase I HV Study

Mesenchymal Stem Cells Preconditioned with Myeloma Cells from High-Risk Patients Support the Growth of Myeloma Cells from Low-Risk Patients

Sucrosomial Technology Is Able to Promote Ferric Iron Absorption: Pre-Clinical and Clinical Evidences

Ferritinophagy and Cell Cycle Control

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

ASN002: A Potent Dual SYK/JAK Inhibitor Currently in a Phase I/II Study Shows Strong Antitumor Activity in Preclinical Studies

Recombinant FVIIIFc-VWF-XTEN Demonstrates Significant Bioavailability Following Subcutaneous Administration in Hemophilia A Mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only